Latest Announcements

Investor Announcement,

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"